Ii-Key-SARS-CoV-2 vaccine generates vaccine-specific antibodies and T cell responses in a transgenic mouse model The Ii-Key vaccine elicits both CD4+ T Helper cell (Th1) and CD8+ responses that are ...
Generex Biotechnology Expands Medical Device Portfolio With Acquisition of Olaregen Therapeutix Inc.
Generex Biotechnology Corporation (OTC:GNBT) announced today the signing of a Letter of Intent to acquire 51 percent of Olaregen Therapeutix Inc., a New York-based regenerative medicine company.
MIRAMAR, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) ("Generex" or the "Company"), an innovative and integrated healthcare holding company ...
Submitted proposal to BARDA for start-to-finish funding to develop an approved, commercial Ii-Key peptide vaccine against the SARS-CoV-2 coronavirus SARS-CoV-2 epitope identification and selection ...
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into ...
WORCESTER, Mass. and TORONTO, Feb. 12, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer ...
Generex to receive $10M in common stock, a warrant, & $1M in R&D funding WORCESTER, Mass. and TORONTO, April 23, 2015 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) ...
Positive interim results from Phase 2b breast cancer study of AE37 presented last month at a major scientific breast cancer conference enable update to clinical development & regulatory strategy and ...
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced an ...
MIRAMAR, Fla., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced that the pay day for the two previously announced ...
collaboration with Dr. Bing Sun of the Chinese Academy of Science (IBC) in Shanghai to develop a SARS vaccine. Sun has done pioneering work isolating SARS genes which can be used in a DNA vaccine.
Generex, a biotech company based in Miramar, issued a shareholder alert Wednesday warning that allegedly illicit activity has adversely affected its share price. The company said it believes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results